(Q38213650)

31 August 2017

title

Transarterial chemoembolization and sorafenib in hepatocellular carcinoma (English)

1 reference

31 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giuseppe Cabibbo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giuseppe Lombardi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Rodolfo Sacco

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Silvia Tremosini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giovanni Galati

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Giancarlo Mazza

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gennaro Gadaleta-Caldarola

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Michela Antonucci

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

22 May 2014

1 reference

Expert Review of Anticancer Therapy

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

831-845

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24850249%20AND%20SRC:MED&resulttype=core&format=json

Hepatocellular cancer: optimal strategies for screening and surveillance

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Loco-regional treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Novel advancements in the management of hepatocellular carcinoma in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Intermediate hepatocellular carcinoma: current treatments and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Multimodal approaches to the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Emerging targeted strategies in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Assessment of treatment response in hepatocellular carcinoma: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Normalization of the vasculature for treatment of cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Nonadherence to guidelines in the management of hepatocellular carcinoma: an Italian or universal phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

The intermediate hepatocellular carcinoma stage: Should treatment be expanded?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.920694

10.1586/14737140.2014.920694

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n6a3cmweerfupl2utdv4fmg2ai

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_n6a3cmweerfupl2utdv4fmg2ai

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n6a3cmweerfupl2utdv4fmg2ai

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/n6a3cmweerfupl2utdv4fmg2ai

1 reference